ACHV

Business Context and Reporting Period

Company: OncoGenex Pharmaceuticals, Inc. (Note: Metadata referenced "ACHIEVE LIFE SCIENCES, INC." but the filing text identifies the registrant as OncoGenex Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: A biopharmaceutical company developing therapies to address treatment resistance in cancer patients. The company's primary focus is the development of OGX-011, a clusterin inhibitor, under a collaboration agreement with Teva Pharmaceutical Industries Ltd.

Key Financial Metrics

Liquidity: As of March 31, 2010, the company held $45.5 million in cash and cash equivalents and $2.1 million in short-term investments. Management believes these resources are sufficient to fund planned operations into 2012.

Material Changes vs. Prior Period

• Revenue Recognition: The company recorded $4.7 million in collaboration revenue in Q1 2010, compared to zero in Q1 2009. This revenue stems from the Teva Collaboration Agreement, consisting of $1.9 million in amortized deferred revenue and $2.8 million in reimbursable manufacturing costs.
• Expense Increase: Total expenses rose to $7.7 million from $2.5 million year-over-year. Research and Development (R&D) expenses increased significantly to $6.4 million (from $1.7 million) due to manufacturing costs and upfront clinical trial costs for OGX-011 Phase III trials.
• Cash Flow: Net cash used in operating activities increased to $17.1 million from $3.0 million, driven by higher R&D spending and payments of milestone amounts to Isis Pharmaceuticals and the University of British Columbia.
• Balance Sheet: Total assets decreased from $69.0 million (Dec 31, 2009) to $56.4 million, primarily due to the use of cash to fund operations and the payment of accrued liabilities.

Guidance, Outlook, and Risks

Outlook and Guidance:

• Clinical Trials: The company expects to initiate three Phase 3 trials for OGX-011: the SATURN trial (second-line prostate cancer) in Q2 2010, a first-line prostate cancer trial in Q3 2010, and a non-small cell lung cancer (NSCLC) trial in early 2011.
• Funding Commitment: OncoGenex is required to contribute $30 million toward the Clinical Development Plan. As of March 31, 2010, $5.3 million has been incurred, leaving a remaining commitment of $24.6 million.
• Cash Runway: Management projects current capital resources will fund operations into 2012, covering the accrual of planned Phase 3 trials.

Risks and Contingencies:

• Dependency on Teva: Future success is heavily dependent on Teva's commitment and ability to develop and commercialize OGX-011.
• Regulatory and Clinical Risk: There is no guarantee that product candidates will obtain regulatory approval or that clinical trials will yield positive results.
• Lease Obligations: The company faces a liability of $4.3 million related to excess office space in Bothell, Washington, which it is attempting to sublet or exit.
• Intellectual Property: The company must pay royalties and milestone payments to Isis Pharmaceuticals and the University of British Columbia, including a potential $20 million milestone to Isis upon a change of control.

Investor Verification Checklist

• Revenue Sustainability: Verify the timing and likelihood of future milestone payments from Teva, as the company does not expect any in 2010.
• Cash Burn Rate: Monitor the $17.1 million cash burn in Q1 2010 against the $45.5 million cash balance to assess the runway into 2012.
• Clinical Trial Initiation: Confirm the initiation dates for the SATURN trial and the first-line prostate cancer trial as scheduled for 2010.
• Lease Liability Resolution: Track progress on subletting or exiting the Bothell, Washington facility to mitigate the $4.3 million restructuring liability.
• Third-Party Obligations: Review the specific terms of royalty and milestone payments due to Isis Pharmaceuticals and the University of British Columbia upon future commercialization or change of control events.